Geoff Meacham of Barclays probes on the pharma segment, some product cycles coming in, expectations about durability of pricing & innovation in the immunology segment. $JNJ CFO said Dominic Caruso said both Guselkumab & Sirukumab are different mechanisms of actions in the current product set. Pricing already have significant gross to net discounts.
$FTR reorganized its business structure with the creation of new consumer and commercial business. The company said that the previous structures were more regionally focused and it had seven regions structure before the reorganization.
$PCLN believes that over the next decade China will continue to be
one of the largest opportunities for travel growth in terms of increasing market
share for the company. $PCLN also sees opportunities to increase domestic market
share in the US.
$PRGO said that in the Consumer Healthcare business, it has been seeing certain pricing pressure. Therefore, across categories $PRGO competes in, it has competitive pricing. The company expects pricing pressure to continue in different segments going forward. But given the growth in new products, $PRGO expects to overcome the pricing challenges.